Clinical trials: Blood-Borne Infections
HIV Infections
Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.
- Trial name
- NCT00902824
- Testing
- ADVAX, TBC-M4
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Human Immunodeficiency Virus
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body.
- Trial name
- NCT02531295
- Testing
- Euphorbia kansui extract powder prepared as tea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
HIV Infections
Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections
Multinational Observational Cohort of HIV and other Infections (MOCHI). This observational study is to gain information regarding the number of new HIV infections among people who engage in behaviors that make them vulnerable to…
- Trial name
- MOCHI (NCT05147519)
- Testing
- Novel interventions to achieve HIV remission
- Where
- 4 sites in Kenya, Nigeria and 2 more
- Volunteers
- 2,500 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Tuberculosis, HIV Coinfection
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV).
- Conditions
- Tuberculosis, HIV Coinfection, Tuberculosis Infection
- Trial name
- TB_GAPS (NCT05342064)
- Testing
- patient-centered TB preventive therapy, TB preventive therapy adherence support
- Where
- 5 sites in Eswatini, Lesotho and 3 more
- Volunteers
- 6,500 people
- Sponsor
- Baylor College of Medicine
Hepatitis C
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
- Trial name
- REACT (NCT02625909)
- Testing
- SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 222 people
- Sponsor
- Kirby Institute
Chronic Hepatitis B Infection
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03208998
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Ditan Hospital
HIV Infections
Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults
Vaccines have been very successful in preventing viral infections such as hepatitis B and the measles. Viral vaccines work by causing a person's immune system to make cells that will work against the virus.
- Trial name
- NCT00623753
- Testing
- EnvDNA, PolyEnv1, EnvPro
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
HIV Infections
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
The purpose of the study is to study the effects of BMS-955176 on the single-dose PK parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin
- Trial name
- NCT02578277
- Testing
- CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex
To study the safety and pharmacokinetics (blood levels) of recombinant human CD4 immunoglobulin (rCd4-IgG) in patients with AIDS or AIDS related complex (ARC) who have failed or declined therapy with zidovudine (AZT).
- Trial name
- NCT00000675
- Testing
- CD4-IgG
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Squamous Cell Carcinoma, HIV Infections
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA.
- Trial name
- ACTION HIV (NCT05328765)
- Where
- 11 sites in Argentina, Brazil and 3 more
- Volunteers
- 369 people
- Sponsor
- Latin American Cooperative Oncology Group
HIV Infections, Hyperlipidemia
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
The purpose of this research is to study the effects of rosiglitazone, a drug usually taken for Type II diabetes, on HIV-associated hyperlipidemia.
- Trial name
- NCT00006493
- Testing
- Rosiglitazone
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
HIV Infections
Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads
This study will look at people who have been taking anti-HIV drugs but still have detectable levels of HIV. The purpose of the study is to find out what happens in those people who change anti-HIV drugs when their viral load…
- Trial name
- NCT00036465
- Testing
- Treatment regimen change
- Where
- 23 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Project to Enhance Patient-Health Engagement in HIV Infection
The importance of patient involvement in their care is emerging as a crucial element in the active management of chronic conditions, including HIV infection.
- Trial name
- HIV-IN-ACTION (NCT07571044)
- Testing
- patient engagement
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coronary Artery Disease, Atherosclerosis, Coronary
HIV Infection And Evolvement of Atherosclerotic Plaque
In a prospective multi-center observational study, 200 HIV-infected patients treated with antiretroviral treatment (ART) and who suffered from coronary artery disease (CAD) will be enrolled.
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Hiv, HIV Infections
- Trial name
- HIVE (NCT04810364)
- Testing
- Quantitative coronary angiography, intravascular imaging with percutaneous intervention
- Where
- 2 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Central Clinical Hospital of the Russian Academy of Sciences
Human Immunodeficiency Virus Infection
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when…
- Trial name
- PROGRESS (NCT00711009)
- Testing
- lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
- Where
- 37 sites in United States, Canada and 5 more
- Volunteers
- 206 people
- Sponsor
- Abbott
HIV Infections, Lipoatrophy
Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
Background: Stavudine-containing regimens are associated with a potential for lipoatrophy and dyslipidemia. We assessed the safety and efficacy of reducing the dose of stavudine compared to switching to tenofovir or maintaining…
- Trial name
- NCT00312832
- Testing
- switching; dose reduction
- Volunteers
- 60 people
- Sponsor
- Hospital Clinic of Barcelona
HIV/AIDS, Myocardial Infarction
Inflammation and Cardiovascular Health in Women
Systemic immune activation and inflammation are believed to play a significant role in the development and clinical course of myocardial infarction (MI).
- Trial name
- NCT04224181
- Testing
- Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HIV Infections, HIV Wasting Syndrome
A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements
To compare a caloric supplement containing peptides and medium-chain triglycerides, a caloric supplement containing whole protein and long-chain triglycerides, and no caloric supplement for the prevention of weight loss in…
- Trial name
- NCT00001077
- Testing
- Multivitamin and mineral supplements, Peptamen, NuBasics
- Where
- 17 sites in United States
- Volunteers
- 536 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Partners PrEP Program
Through close collaboration with the Ugandan Ministry of Health, the investigators plan to provide PrEP for HIV-negative members of HIV serodiscordant couples by launching PrEP delivery within 12 public ART clinics in Kampala…
- Trial name
- PPP (NCT03586128)
- Testing
- PrEP, ART
- Where
- Uganda
- Volunteers
- 1,381 people, healthy volunteers welcome
- Sponsor
- University of Washington
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.